The high risk of pancreatic cancer is originally related to these 5 new gene changes

Share This Post

In the largest genome-wide pancreatic cancer study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute and collaborators in more than 80 other institutions worldwide have discovered mutations in five new regions of the human genome This may increase the risk of pancreatic cancer.

The discovery was published in Nature Communications on February 8, and scientists analyzed more than 11.3 million mutations in 21,536 people. These new discoveries have prompted another step in grasping the genetic changes associated with pancreatic cancer risk factors, which can better understand the pathogenesis of pancreatic cancer and guide the research of more targeted treatment methods and early detection and screening methods. Newly identified genetic variants on human chromosomes 1 (position 1p36.33), 7 (position 7p12), 8 (position 8q21.11), 17 (position 17q12), and 18 (position 18q21.32) increase pancreatic cancer risk . The presence of each copy in these genomes increases the risk of pancreatic cancer by 15-25%.

At the individual level, there is a mutation that does not completely predict cancer, because they are only associated with a modest change in risk, but when they are combined, they help to more fully understand the pathogenesis of pancreatic cancer. The researchers will continue to delve into the genetic characteristics of pancreatic cancer, and there are many genetic factors that we do not know about the risk of pancreatic cancer.

Understanding the genetic mutation mechanism of pancreatic cancer can better develop targeted drugs, which will set off a wave of pancreatic cancer treatment. There are many targeted drugs on the market for other cancers. For different types of mutant genes, targeted drugs are used to reduce side effects and improve efficacy. Therefore, it is recommended that cancer patients must pay attention to the benefit space of targeted therapy and conduct genetic testing before medication.

The large authoritative companies that can choose to carry out genetic testing for cancer are American Kerrys, American Foundation, and the domestic ones have Pansheng, Shihe Gene. The Global Oncologist Network can assist patients with genetic testing throughout the process. Patients can consult the Global Oncologist Network for consultation .

 

Reference : https://medicalxpress.com/news/2018-02-genetic-linked-pancreatic-cancer.html

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy